Bronchial thermoplasty for severe asthma

Momen M. Wahidi, Monica Kraft

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

Bronchial thermoplasty (BT) is a novel treatment of patients with severe asthma who continue to be symptomatic despite maximal medical treatment. It aims to reduce the smooth muscle mass in the airways by delivering controlled thermal energy to the airway walls during a series of three bronchoscopies. Randomized controlled clinical trials of BT in severe asthma have not been able to show a reduction in airway hyperresponsiveness or change in FEV 1 but have suggested an improvement in quality of life, as well as a reduction in the rate of severe exacerbations, emergency department visits, and days lost from school or work. Strict inclusion and exclusion criteria of these trials resulted in the elimination of patients with severe asthma who experienced more than three exacerbations per year. Therefore, the generalizability of this treatment to the broader severe asthma population still needs to be determined. The short-termadverse events consist primarily of airway inflammation and occasionally more severe events requiring hospitalization. Long-term safety data are evolving and have shown thus far clinical and functional stability up to 5 years after BT treatment. Additional studies on BT are needed to establish accurate phenotyping of positive responders, durability of effect, and long-term safety.

Original languageEnglish (US)
Pages (from-to)709-714
Number of pages6
JournalAmerican journal of respiratory and critical care medicine
Volume185
Issue number7
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Asthma
Safety
Bronchoscopy
Therapeutics
Smooth Muscle
Hospital Emergency Service
Hospitalization
Randomized Controlled Trials
Hot Temperature
Quality of Life
Inflammation
Population

Keywords

  • Asthma
  • Bronchoscopy
  • Treatment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Bronchial thermoplasty for severe asthma. / Wahidi, Momen M.; Kraft, Monica.

In: American journal of respiratory and critical care medicine, Vol. 185, No. 7, 01.04.2012, p. 709-714.

Research output: Contribution to journalReview article

@article{a17a5775cd1e46f7a2d01a68b9a31173,
title = "Bronchial thermoplasty for severe asthma",
abstract = "Bronchial thermoplasty (BT) is a novel treatment of patients with severe asthma who continue to be symptomatic despite maximal medical treatment. It aims to reduce the smooth muscle mass in the airways by delivering controlled thermal energy to the airway walls during a series of three bronchoscopies. Randomized controlled clinical trials of BT in severe asthma have not been able to show a reduction in airway hyperresponsiveness or change in FEV 1 but have suggested an improvement in quality of life, as well as a reduction in the rate of severe exacerbations, emergency department visits, and days lost from school or work. Strict inclusion and exclusion criteria of these trials resulted in the elimination of patients with severe asthma who experienced more than three exacerbations per year. Therefore, the generalizability of this treatment to the broader severe asthma population still needs to be determined. The short-termadverse events consist primarily of airway inflammation and occasionally more severe events requiring hospitalization. Long-term safety data are evolving and have shown thus far clinical and functional stability up to 5 years after BT treatment. Additional studies on BT are needed to establish accurate phenotyping of positive responders, durability of effect, and long-term safety.",
keywords = "Asthma, Bronchoscopy, Treatment",
author = "Wahidi, {Momen M.} and Monica Kraft",
year = "2012",
month = "4",
day = "1",
doi = "10.1164/rccm.201105-0883CI",
language = "English (US)",
volume = "185",
pages = "709--714",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "7",

}

TY - JOUR

T1 - Bronchial thermoplasty for severe asthma

AU - Wahidi, Momen M.

AU - Kraft, Monica

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Bronchial thermoplasty (BT) is a novel treatment of patients with severe asthma who continue to be symptomatic despite maximal medical treatment. It aims to reduce the smooth muscle mass in the airways by delivering controlled thermal energy to the airway walls during a series of three bronchoscopies. Randomized controlled clinical trials of BT in severe asthma have not been able to show a reduction in airway hyperresponsiveness or change in FEV 1 but have suggested an improvement in quality of life, as well as a reduction in the rate of severe exacerbations, emergency department visits, and days lost from school or work. Strict inclusion and exclusion criteria of these trials resulted in the elimination of patients with severe asthma who experienced more than three exacerbations per year. Therefore, the generalizability of this treatment to the broader severe asthma population still needs to be determined. The short-termadverse events consist primarily of airway inflammation and occasionally more severe events requiring hospitalization. Long-term safety data are evolving and have shown thus far clinical and functional stability up to 5 years after BT treatment. Additional studies on BT are needed to establish accurate phenotyping of positive responders, durability of effect, and long-term safety.

AB - Bronchial thermoplasty (BT) is a novel treatment of patients with severe asthma who continue to be symptomatic despite maximal medical treatment. It aims to reduce the smooth muscle mass in the airways by delivering controlled thermal energy to the airway walls during a series of three bronchoscopies. Randomized controlled clinical trials of BT in severe asthma have not been able to show a reduction in airway hyperresponsiveness or change in FEV 1 but have suggested an improvement in quality of life, as well as a reduction in the rate of severe exacerbations, emergency department visits, and days lost from school or work. Strict inclusion and exclusion criteria of these trials resulted in the elimination of patients with severe asthma who experienced more than three exacerbations per year. Therefore, the generalizability of this treatment to the broader severe asthma population still needs to be determined. The short-termadverse events consist primarily of airway inflammation and occasionally more severe events requiring hospitalization. Long-term safety data are evolving and have shown thus far clinical and functional stability up to 5 years after BT treatment. Additional studies on BT are needed to establish accurate phenotyping of positive responders, durability of effect, and long-term safety.

KW - Asthma

KW - Bronchoscopy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84858014511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858014511&partnerID=8YFLogxK

U2 - 10.1164/rccm.201105-0883CI

DO - 10.1164/rccm.201105-0883CI

M3 - Review article

C2 - 22077066

AN - SCOPUS:84858014511

VL - 185

SP - 709

EP - 714

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 7

ER -